Education
About Us
Working with TipRanks
Follow Us
Moderna (MRNA)
NASDAQ:MRNA
MRNA Analyst Ratings
Hold
3 Buy
11 Hold
4 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRNA Stock 12 Month Forecast
Average Price Target
$51.29
▲(104.26% Upside)
| Highest Price Target$212.00 | Average Price Target$51.29 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
RBC Capital
Reiterated
04/03/25
Bernstein
Reiterated
04/02/25
Brookline Capital Markets
Reiterated
03/31/25
Citi
Reiterated
03/26/25
J.P. Morgan
Reiterated
03/21/25
Berenberg Bank
Reiterated
03/06/25
Leerink Partners
Reiterated
03/03/25
Morgan Stanley
Reiterated
02/18/25
Barclays
$111→$45
Hold
79.21%
Upside
Downgraded
02/18/25
Moderna downgraded to Equal Weight from Overweight at BarclaysModerna downgraded to Equal Weight from Overweight at Barclays
Bank of America Securities
$34→$32
Sell
27.44%
Upside
Reiterated
02/17/25
Moderna's Financial Challenges and Pipeline Setbacks Prompt 'Sell' Rating by Analyst Tim Anderson
Goldman Sachs
$99→$51
Hold
103.11%
Upside
Reiterated
02/14/25
Could Modernas (MRNA) 65% Stock Plunge Entice a Takeover? - TipRanks.comLead MRNA analyst Salveen Richter notes Modernas long-term potential but concludes the stock lacks positive asymmetry in the near term.
Wolfe Research
$35→$25
Sell
-0.44%
Downside
Reiterated
02/14/25
Moderna's Financial Uncertainty and Strategic Risks Drive Sell Rating by Alexandria Hammond
Needham
―
Hold
―
Reiterated
02/14/25
Cautious Optimism: Moderna's Hold Rating Amid Revenue Challenges and Long-Term Potential
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
RBC Capital
Reiterated
04/03/25
Bernstein
Reiterated
04/02/25
Brookline Capital Markets
Reiterated
03/31/25
Citi
Reiterated
03/26/25
J.P. Morgan
Reiterated
03/21/25
Berenberg Bank
Reiterated
03/06/25
Leerink Partners
Reiterated
03/03/25
Morgan Stanley
Reiterated
02/18/25
Barclays
$111→$45
Hold
79.21%
Upside
Downgraded
02/18/25
Moderna downgraded to Equal Weight from Overweight at BarclaysModerna downgraded to Equal Weight from Overweight at Barclays
Bank of America Securities
$34→$32
Sell
27.44%
Upside
Reiterated
02/17/25
Moderna's Financial Challenges and Pipeline Setbacks Prompt 'Sell' Rating by Analyst Tim Anderson
Goldman Sachs
$99→$51
Hold
103.11%
Upside
Reiterated
02/14/25
Could Modernas (MRNA) 65% Stock Plunge Entice a Takeover? - TipRanks.comLead MRNA analyst Salveen Richter notes Modernas long-term potential but concludes the stock lacks positive asymmetry in the near term.
Wolfe Research
$35→$25
Sell
-0.44%
Downside
Reiterated
02/14/25
Moderna's Financial Uncertainty and Strategic Risks Drive Sell Rating by Alexandria Hammond
Needham
―
Hold
―
Reiterated
02/14/25
Cautious Optimism: Moderna's Hold Rating Amid Revenue Challenges and Long-Term Potential
MRNA Analyst Recommendation Trends
Rating
Dec 24
Jan 25
Feb 25
Mar 25
Apr 25
Strong Buy
6
6
4
4
2
Buy
0
0
0
0
0
Hold
19
22
20
23
16
Sell
7
12
13
13
8
Strong Sell
0
0
0
0
0
total
32
40
37
40
26
Each month's total comprises the sum of three months' worth of ratings.
MRNA Financial Forecast
MRNA Stock Forecast FAQ
What is MRNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Moderna’s 12-month average price target is $51.29.
What is MRNA’s upside potential, based on the analysts’ average price target?
Moderna has 104.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRNA a Buy, Sell or Hold?
Moderna has a consensus rating of Hold which is based on 3 buy ratings, 11 hold ratings and 4 sell ratings.
What is Moderna’s price target?
The average price target for Moderna is $51.29. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $212.00 ,the lowest forecast is $25.00. The average price target represents 104.26% Increase from the current price of $25.11.
The highest analyst price target is $212.00 ,the lowest forecast is $25.00. The average price target represents 104.26% Increase from the current price of $25.11.
What do analysts say about Moderna?
Moderna’s analyst rating consensus is a Hold. This is based on the ratings of 18 Wall Streets Analysts.
How can I buy shares of MRNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.